Iparomlimab and Tuvonralimab (QL1706) for Intermediate Trophoblastic Tumors

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

April 15, 2025

Primary Completion Date

April 16, 2027

Study Completion Date

April 16, 2028

Conditions
Intermediate Trophoblastic Tumor
Interventions
DRUG

QL1706

5 mg/kg, IV infusion, Q3W (D1)

DRUG

Chemotherapy

FAEV, EMA/EP, EMA/CO, or TP/TE.

Trial Locations (1)

100730

RECRUITING

Peking Union Medical College Hospital, Beijing

All Listed Sponsors
collaborator

Shengjing Hospital

OTHER

collaborator

Obstetrics & Gynecology Hospital of Fudan University (Shanghai Red House Ob & Gyn Hospital)

UNKNOWN

collaborator

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

OTHER

collaborator

Henan Cancer Hospital

OTHER_GOV

collaborator

Gansu Provincial Maternal and Child Health Care Hospital

OTHER

collaborator

Dalian women and children's medical group

UNKNOWN

collaborator

The First Affiliated Hospital of Xiamen University

OTHER

collaborator

Sichuan Cancer Hospital and Research Institute

OTHER

lead

Peking Union Medical College Hospital

OTHER